Category Archives: Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) are known to have a potential for articular cartilage regeneration. However, most studies focused on focal cartilage defect through surgical implantation. For the treatment of generalized cartilage loss in osteoarthritis, an alternative delivery strategy would be more appropriate. The purpose of this study was to assess the safety and efficacy of intra-articular injection of autologous adipose tissue derived MSCs (AD-MSCs) for knee osteoarthritis. We enrolled 18 patients with osteoarthritis of the knee and injected AD MSCs into the knee. The phase I study consists of three dose-escalation cohorts; the low-dose (1.0 10(7) cells), mid-dose (5.0 10(7)), and high-dose (1.0 10(8)) group with three patients each. The phase II included nine patients receiving the high-dose. The primary outcomes were the safety and the Western Ontario and McMaster Universities Osteoarthritis index (WOMAC) at 6 months. Secondary outcomes included clinical, radiological, arthroscopic, and histological evaluations. There was no treatment-related adverse event. The WOMAC score improved at 6 months after injection in the high-dose group. The size of cartilage defect decreased while the volume of cartilage increased in the medial femoral and tibial condyles of the high-dose group. Arthroscopy showed that the size of cartilage defect decreased in the medial … Continue reading →

1 Dr Fayez Fouda Mesenchymal Stem Cells By: doaa gado … Continue reading →

Dr Fayez Fouda Mesenchymal Stem Cells By: doaa gado … Continue reading →

[Interview with Author] Use of nanoparticles to monitor mesenchymal stem cells transplanted KJU - Video Interview with Author - 2015-04 Title: Use of nanoparticles to monitor human mesenchymal stem cells transplanted into penile cavernosum of rats with erectile dysfunction Authors:... By: KJUrology … Continue reading →

Rice University and Texas Children's Hospital scientists are using stem cells from amniotic fluid to promote the growth of robust, functional blood vessels in healing hydrogels. In new experiments, the lab of bioengineer Jeffrey Jacot combined versatile amniotic stem cells with injectable hydrogels used as scaffolds in regenerative medicine and proved they enhance the development of vessels needed to bring blood to new tissue and carry waste products away. The results appear in the Journal of Biomedical Materials Research Part A. Jacot and his colleagues study the use of amniotic fluid cells from pregnant women to help heal infants born with congenital heart defects. Such fluids, drawn during standard tests, are generally discarded but show promise for implants made from a baby's own genetically matched material. He contends amniotic stem cells are valuable for their ability to differentiate into many other types of cells, including endothelial cells that form blood vessels. "The main thing we've figured out is how to get a vascularized device: laboratory-grown tissue that is made entirely from amniotic fluid cells," Jacot said. "We showed it's possible to use only cells derived from amniotic fluid." In the lab, researchers from Rice, Texas Children's Hospital and Baylor College … Continue reading →

Frederick, MD (PRWEB) April 09, 2015 Based upon strong market demand, RoosterBio Inc has announced the commercial launch of RoosterVial-hBM-50M MSC, a single vial containing 50 million human bone-marrow derived mesenchymal stem/stromal cells. This unprecedented, ultra-high cell number product configuration enables Regenerative Medicine organizations to accelerate scale-up and product development activities. RoosterBios core technology, which includes cell and media systems, allows tissue engineers, biofabricators, 3D bioprinters and cell therapy developers to instantly scale up, using simplified and standardized methods. The 50 million hMSC vial delivers immediate cell biomass without the need for prior expansion. This results in saving significant time, resources and expense during bioprocess scale-up optimization. Since the system contains the most well-characterized hMSCs available on the market, the industry is assured robust and reproducible results. As with other RoosterBio products, this 50 million cell product is capable of greater than 100-fold expansion (>5 billion cells) within two weeks when cultured in RoosterBio medium. Prior to this technology, obtaining such cell numbers so rapidly was virtually impossible. RoosterBio continues to broaden their portfolio of product formats, providing solutions for an extensive range of Regenerative Medicine therapeutic categories. The evolving product portfolio enables researchers and product developers to perform small … Continue reading →

PHILADELPHIA -- The American Association for Cancer Research (AACR) is honoring Owen N. Witte, MD, founding director of the Eli & Edythe Broad Center of Regenerative Medicine & Stem Cell Research and distinguished professor of microbiology, immunology, and molecular genetics at the University of California, Los Angeles, with the 55th annual AACR G.H.A. Clowes Memorial Award at the AACR Annual Meeting 2015, to be held in Philadelphia, April 18-22. Witte, who is also a Howard Hughes Medical Institute investigator and an elected fellow of the AACR Academy, is being recognized for his many contributions to the understanding of human leukemias, immune disorders, and epithelial cancer stem cells. Witte's work, which contributed to the development of several approved targeted therapies, has transformed the lives of patients with Philadelphia chromosome-positive leukemias and B-cell malignancies. He will present his lecture, "Finding Therapeutic Targets for Aggressive Prostate Cancer," Monday, April 20, 5:30 p.m. ET, in the Grand Ballroom of the Pennsylvania Convention Center. The AACR and Eli Lilly and Company established the G.H.A. Clowes Memorial Award in 1961 to honor Dr. G.H.A. Clowes, a founding member of the AACR and research director at Eli Lilly. This award recognizes an individual with outstanding recent accomplishments … Continue reading →

Beverly Hills, California (PRWEB) April 07, 2015 Dr. Raj, the top Orthopedic Surgeon in Beverly Hills and Los Angeles, is now offering stem cell therapy to heal chronic tendonitis. The treatment works exceptionally well for those suffering from tendonitis of the rotator cuff, achilles, elbow and knee. For more information and scheduling, call (310) 247-0466. As a pioneer in regenerative medicine, Dr. Raj has been helping patients with degenerative arthritis achieve relief and avoid joint replacements for years with stem cell procedures. By adding the procedures for tendonitis, Dr. Raj is now helping patients avoid potentially risky surgeries and get back to being more active for soft tissue related pain. "Surgery for tendonitis is often not 100% successful for patients, and the rehabilitation period may take six months," states Dr. Raj. "With the stem cell therapy, pain relief is quick and athletes get back to sports faster!" Regenerative medicine for tennis elbow has been shown in research studies to be effective at relief and helping avoid surgery. A 2013 study out of South Florida showed that 28 out of 30 patients with chronic tennis elbow avoided surgery and got back to being very active. For several years in a row, … Continue reading →

Miami, FL (PRWEB) April 06, 2015 Regenestem Network, a subsidiary of the Global Stem Cells Group, has announced plans to attend the 23rd Annual World Congress on Anti-Aging Medicine (a4m) at the Diplomat Resort and Spa in Hollywood, Fla. Hosted by the American Academy of Anti-aging Medicine, the conference will be attended by physicians and medical practitioners from around the world. Regenestem Network plans to showcase its upcoming stem cell training course, Adipose Derived and Bone Marrow Stem Cell course, with classes scheduled to be held May 9-10 and June 15-16, 2015 in Miami. The intensive, two-day course covers the latest technology and procedures in adipose and bone marrow stem cell therapies. Participants learn skills that can be used in their own practice and for career advancement. A4m Conference Keynote speakers include Daniel G. Amen, MD, David Perlmutter, MD, FACN, ABIHM, and Gary Small, MD. All three will focus on disease prevention and optimized health through a proactive treatment approach. These world-renown speakers are scheduled to deliver insightful presentations, the latest research and breakthrough therapies in anti-aging medicine. To learn more about the 23rd Annual World Congress on Anti-Aging Medicine, visit the a4m website. For more information on the Regenestem … Continue reading →

TORRANCE, Calif.--(BUSINESS WIRE)--Celprogen Inc., a leader in the Stem Cell Research and Therapeutics industry for the development of stem cell technologies for regenerative medicine, today announced that they have developed STEMC5007, a synthetic molecule that is capable of stimulating and activating the internal stem cell population. This molecule can be administered by the following methods: intravenous, intra-peritoneal and intramuscular injections, and oral doses. The molecule STEMC5007 activates adult stem cell populations including progenitor stem cells, mesenchymal, skin, human hair follicle stem cells and adipose stem cells. The present invention relates to increasing the stem cell population within the human organ systems without isolating and expanding the stem cells in a laboratory environment prior to administration of the stem cells back into the human body. The molecule STEMC5007 has been developed and optimized by Celprogen utilizing stem cell tissue culture technology. This technology will have a greater impact for patients that would require stem cell transplants; it works with the existing stem cell population in the individual's system. This molecule STEMC5007 is an interesting factor to be added to the regenerative medicine therapy and wound healing. About Celprogen Inc. Celprogen Inc. is a global Stem Cell Research & Therapeutics company which … Continue reading →